Drug Trial Radar · NCT02786485
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 2016
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, multicenter, open-label, non-randomized study of matched unrelated donor BPX-501 T cell infusion in adult subjects with hematological malignancies presenting with recurrent disease minimal residual disease (MRD) post-allogeneic transplant.
Conditions
- Leukemia
- Myelodysplastic Syndromes
- Lymphomas
- Multiple Myeloma
- Other High-risk Hematological Malignancies
Interventions
rivogenlecleucelBiological
T cells transduced with iCasp safety switch
RimiducidDrug
administered to treat GVHD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: 30 days after last dose of study drug (BPX-501 and/or rimiducid)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.